H.C. Wainwright has downgraded Syros Pharmaceuticals (NASDAQ:SYRS) to neutral from buy, citing Tuesday’s announcement that a ...

H.C. Wainwright analyst Joseph Pantginis says Leerink this morning downgraded Compass Therapeutics (CMPX) saying the company’s biliary ...

H.C. Wainwright analyst Kevin Dede reiterated a Hold rating on LM Funding America (LMFA – Research Report) today. The company’s ...

Ardelyx (NASDAQ:ARDX) shares were down over 5% after H.C. Wainwright downgraded the rating for the biopharmaceutical firm, ...

We recently compiled a list of the 15 AI News That Should Not Be Ignored. In this article, we are going to take a look at ...

H.C. Wainwright reinstated coverage of Opus Genetics (IRD) with a Buy rating and $8 price target The firm believes inherited ...

On Thursday, Geron Corp (GERN) stock saw a decline, ending the day at $3.71 which represents a decrease of $-0.16 or -4.13% from the prior close of $3.87. The stock opened at $3.86 and touched a low ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 30.29% ...

Ardelyx (NASDAQ:ARDX) shares were down over 5% after H.C. Wainwright downgraded the rating for the biopharmaceutical firm, saying that it anticipates a substantial drop in the company's kidney ...

On Tuesday, H.C. Wainwright initiated coverage on Geron (NASDAQ:GERN) Corporation (NASDAQ:GERN) with a Buy rating and a price target of $8.00. The optimism stems from the successful launch of the ...

On Tuesday, H.C. Wainwright maintained its Buy rating and $30.00 price target for Adverum Biotechnologies (NASDAQ:ADVM), expressing optimism about the company's upcoming clinical updates.